

Mark Yockey on Keeping It Simple and Focusing on What Matters

PORTFOLIO MANAGER
Viewpoints

December 2020

Artisan Partners Global Equity Team portfolio manager Mark Yockey and CEO Eric Colson recently sat down for an exclusive conversation about Mark's pursuit of exceptional companies with unique value propositions over the course of the Artisan Global Equity Strategy's 10 years.

The investing environment is obviously currently very interesting—what are some of the exciting areas to you right now?

Mark Yockey: Energy efficiency is a long-term theme that interests us, and we think climate change is a big deal going forward. Buildings generate roughly 40% of global greenhouse gases, and a large percentage of that is for heating and cooling. We think most of the world will want to upgrade HVAC systems to more energy-efficient models. Companies that make energy-efficient heat pumps and companies involved in renewable energy also interest us on a long-term basis. Among the biggest producers of methane gas in the world are cows. We hold a Netherlands-based company that has developed a pill for cows that reduces the amount of methane gas they produce by 30% to 50%. Innovation that offers real solutions like this has the potential to drive growth over the long term, and that's what we look for in an investment.

There are also a lot of advances in health care we find exciting—such as a life-sciences tools company that has a blood test for early cancer detection. The test has the potential to disrupt the oncology market. Using a simple blood draw, the test can detect multiple cancers before patients are symptomatic and their cancer has metastasized—helping diagnose patients in earlier stages with the highest probability of successful treatment and survival. This is a large market opportunity that we estimate is over \$30 billion in the US alone.

Do you see the digitalization and e-commerce themes continuing?

Mark Yockey: Absolutely. Digitalization is probably going to have as big an impact on the world as the invention of the car back in the 1900s. All these trends have been accelerated by the current health crisis. Business travel, we believe, is going to be significantly diminished from what it would have been otherwise. People are going to go about how they do business in a much different way than before. For instance, in Manhattan right now—and you could replace Manhattan with virtually any big city in the world—there's only about one in six people going to the office, and the rest of the people are working from home. It's good that we've all been able to adapt so quickly. E-commerce is part of that, as are all the different services and businesses that are flourishing because of digitalization. We only expect more of that to happen going forward. So, we think digitalization is a huge deal.

What are some of the big themes looking forward in health care?

Mark Yockey: Health care is really exciting, and the US is really good at it. Part of the reason is the US spends a lot more money on it than anybody else does. The result of that is really good technology, and the US leads the world in advances in a lot of different sectors within health care. In biopharma, we're attracted to companies that provide contract manufacturing and development services. These companies offer access to the growth of biotechnology R&D, while helping minimize the volatility that can come with concentrating exposure in product biotech companies. Another example where drug development risk is lessened is Danish biopharmaceuticals company Ascendis Pharma. The company utilizes its TransCon™



Mark L. Yockey, CFA
Portfolio Manager



Eric C. Colson
CEO, Artisan Partners



technology to develop drugs that provide for the predictable and sustained release of an unmodified parent drug, thereby improving the drug's effect on patients. Since this technology is applied to proven drug targets, development risk is lower compared to other biotech companies.

In biotech, where companies operate in different development stages, how do you build conviction in these names?

Mark Yockey: We try to take as much risk out of the process as we can. We'd much prefer to invest in companies that have a product either on the market or a product that has been de-risked, so it's virtually approved. Our aim is taking out the risk involved in investing in a venture-stage company. We typically get involved when it's in late-stage two, stage three or has been approved. It doesn't always work—sometimes there are disappointments—but by and large, we believe it's a great way to get involved before the market fully values a company.

You seem to keep it quite simple. How do you take what may be complex and boil it down to what matters?

Mark Yockey: The main question we ask is: Is it a good business capable of generating high returns over a long period of time? Commodities-related businesses typically generate commodities-like rates of return over time, whereas high value-added companies with unique intellectual property or business processes can be successful on a long-term basis. The essence is focusing on what allows the company to be successful. What are they doing differently from other people? We look for exceptional companies that we think offer products and services not easily replicated by other companies. If you're doing something different and unique, we find you're often able to charge a premium for it—and companies that can charge a premium tend to be more profitable.

We have a deep research team of experienced analysts, with offices in New York, San Francisco, Singapore and London. Having team members in different parts of the world helps us better understand individual markets and scour the opportunity set for the best growth ideas wherever they exist. Ideas come to us in a few ways. We read a lot. We also have great networks in the marketplace—we're constantly talking to people in business and industry and in government. And up until the last year, we would travel and visit companies. Hopefully we'll get back to doing that soon. But in the meantime, we'll use Zoom and all the other different ways of communicating.

Regarding portfolio construction, how do you think about position sizing and risk management?

Mark Yockey: As you might expect, the biggest holdings are the ones where we have the most conviction. It doesn't mean they're always the ones that go up the most—but if we're doing our job, they hopefully are sometimes. We also look to capitalize on opportunities when other investors are negative—which allows us to build our positions at better prices. We were able to do this when stocks were under so much COVID-related pressure in the spring—and we were able to add some good companies that were a little bit smaller than we might have otherwise invested in.

With the rise of quantitative investing, it's really become evident that the amount of available information and data is massive. How do you manage your time reading and researching and managing your sources of information?

Mark Yockey: Oh, that's impossible to answer. We just read until we can't read anymore, I guess—until it's time for dinner. I think the important thing is to have a deep understanding of certain subjects. You don't want to know just a little bit about a lot—you want to know a lot about what you're invested in. It helps to focus on areas of the world's economy we think are going to offer value and growth going forward; areas like biotech, energy efficiency that we touched on, companies in the branded goods area, like Nestle, which we've owned for a long time. There are a lot of innovative technology-related companies, such as in software, e-commerce and the Internet. Companies that are truly value-added.

Some of our competitors are set up uniquely to use data, but they don't talk to companies or care what companies actually do. That's not how we approach it. We want to understand how companies operate, how they get paid and their future growth prospects. Heaven knows there's plenty of data out there for everybody to use, but I don't think data is the differentiating factor. You can use data to support your analysis, but at the end of the day, we are looking for companies with unique products and services that are not easily replicated.

Given how quickly markets move, it's easy to run the risk of riding a price up, only to then ride it back down. Can you describe your valuation and sell discipline?

Mark Yockey: A lot of growth managers are growth at *any* price, whereas we are growth at a *reasonable* price. We sell things when we think the valuation no longer reflects the underlying fundamentals. We estimate a company's growth rate and compare that to its valuation. Sometimes the growth rate accelerates; sometimes it decelerates, which is a bad thing if the stock is highly valued. We'd much rather invest in companies with stable or rising growth rates than falling growth rates. And hopefully we invest early in a company's growth so we can participate in the upside. If anything, we've been a little



too cautious this year. If we'd held onto some of these companies a little longer, we probably would have done better. But having done this for a while, sometimes being a little cautious is not a bad thing.

You've invested across various market cycles and crisis periods, such as the TMT bubble and the global financial crisis. And over the course of the Global Equity Strategy's 10 years, there has been the euro crisis, Brexit and now the COVID-19 pandemic. How have you been able to navigate these market cycles?

Mark Yockey: I think the important thing is not drinking too much of the Kool-Aid, and when things get overvalued, not being afraid to take some money off the table. At different points in different economic cycles, certain parts of the market can become overvalued. Being willing to step back when everybody gets excited about something can really help over the long term because it means you're less likely to get crushed in a bear market. That's what we try to do.

For more information: Visit www.artisanpartners.com

This commentary represents the views of Mark L. Yockey, portfolio manager of the Artisan Partners Global Equity Team as of 2 Nov 2020 and do not necessarily represent those of Artisan Partners. The views and opinions expressed are based on current market conditions, which will fluctuate, and those views are subject to change without notice. While the information contained herein is believed to be reliable, there is no guarantee to the accuracy or completeness of any statement in the discussion. Any forecasts contained herein are for illustrative purposes only and are not to be relied upon as advice or interpreted as a recommendation.

Current and future holdings are subject to risk. International investments involve special risks, that may in particular cause a loss of principal, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described in Artisan Partners' Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information.

These holdings comprise the following percentages of representative account within the following strategies as of 31 Dec 2020: Artisan Non-U.S. Growth strategy—Ascendis Pharma A/S 1.5%; Nestle SA 3.7%; Artisan Global Equity strategy—Ascendis Pharma A/S 1.3%; Nestle SA 1.0%. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities. Securities named, but not listed here are not held as of the date noted.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This material is provided for informational purposes without regard to your particular investment needs and shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is authorized and regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein.

Artisan Partners is not registered, authorized or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorized or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia. **Bailiwick of Guernsey:** The financial services referred to in this material and this document are not being made available in the Bailiwick of Guernsey (Guernsey) to more than 50 persons in Guernsey and the financial services may not be accepted by more than 50 persons in Guernsey. **Canada:** This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2021 Artisan Partners. All rights reserved.

For Institutional Investors Only—Not for Onward Distribution

A R T I S A N



P A R T N E R S